- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00720356
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bevacizumab together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with erlotinib works after radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
OBJECTIVES:
Primary
- To determine the overall survival of patients with newly diagnosed glioblastoma multiforme (GBM) with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
Secondary
- To determine the 12- and 24-month progression-free survival (PFS) of patients with newly diagnosed GBM with unmethylated MGMT promoter treated with this regimen.
- To assess radiographic response rates.
- To perform correlative tissue assays.
- To collect safety data on the combination of bevacizumab and erlotinib hydrochloride in patients with newly diagnosed GBM with unmethylated MGMT promoter treated with bevacizumab and erlotinib hydrochloride after radiotherapy and temozolomide.
OUTLINE: This is a multicenter study.
Patients undergo radiotherapy (either intensity-modulated radiation therapy or 3-D conformal radiotherapy) once daily 5 days a week and receive oral temozolomide concurrently with radiotherapy once daily for 6 weeks (as planned). Patients whose tumor has a methylated MGMT promoter are removed from study.
Approximately 4 weeks after completion of radiotherapy and temozolomide, patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment with bevacizumab and erlotinib hydrochloride repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at approximately 30 days and then every 3 months thereafter.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32806-2134
- M.D. Anderson Cancer Center at Orlando
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611-3013
- Northwestern University, Northwestern Medical Faculty Foundation
-
Evanston, Illinois, Forenede Stater, 60201-1781
- Evanston Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Neuro-Oncology Associates at Baylor University Medical Center, Dallas
-
Houston, Texas, Forenede Stater, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
Houston, Texas, Forenede Stater, 77030
- The Methodist Hospital Neurological Institute
-
-
Washington
-
Seattle, Washington, Forenede Stater, 19024
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
- Undergoing or plan to undergo treatment with radiotherapy and concurrent temozolomide for 6 weeks
Unmethylated MGMT promoter status must be determined before completing radiotherapy
- Tumor must be MGMT negative to receive bevacizumab and erlotinib hydrochloride
Patients who are post biopsy or tumor resection allowed provided a post-operative MRI is done no more than 96 hours after surgery (in order for an accurate assessment to be done post radiotherapy):
- Evaluable or measurable disease after resection of recurrent tumor is not mandated for eligibility
Patients who started radiotherapy and temozolomide prior to study entry are eligible as long as the gene methylation status is determined before starting bevacizumab and erlotinib hydrochloride
- Radiotherapy plans need to be verified to confirm the treatment plan meets the study requirement based on the PI assessment
- No progressive disease based on MRI or CT scan per the investigators assessment
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Life expectancy > 12 weeks
- WBC > 3,000/μL
- ANC > 1,500/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 10 g/dL
- SGOT/SGPT < 3 times upper limit of normal (ULN)
- Bilirubin < 3 times ULN
- Creatinine < 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No significant medical illness that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate this therapy, or any disease that will obscure toxicity or dangerously alter drug metabolism
No proteinuria at screening, as demonstrated by either of the following:
- Urine protein:creatinine (UPC) ratio < 1.0
- Urine dipstick for proteinuria < 2+ OR ≤ 1g protein by 24-hour urine collection
- No inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg) on antihypertensive medications
- No history of hypertensive crisis or hypertensive encephalopathy
- No New York Heart Association class II-IV congestive heart failure
- No history of myocardial infarction or unstable angina within 6 months prior to study enrollment
- No history of stroke or transient ischemic attack within 6 months of study enrollment
- No symptomatic peripheral vascular disease
- No significant vascular disease (i.e., aortic aneurysm or aortic dissection)
- No evidence of bleeding diathesis or coagulopathy
- No significant traumatic injury within 28 days prior to study enrollment
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- No serious, nonhealing wound, ulcer, or bone fracture
No known HIV positivity
- HIV testing is not required for study participation
- No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
PRIOR CONCURRENT THERAPY:
- No chemotherapy is allowed prior to starting radiotherapy and temozolomide, including polifeprosan 20 with carmustine implant (Gliadel wafers)
- No major surgical procedure or open biopsy within 28 days prior to study enrollment or the anticipation of need for major surgical procedure during the course of the study
- No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
Concurrent nonenzyme-inducing anticonvulsants allowed
- More than 2 weeks (before starting erlotinib hydrochloride and bevacizumab) since prior and no concurrent enzyme-inducing anticonvulsant
- No other concurrent experimental agents
- Not concurrently participating in other clinical trials
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Treatment
erlotinib and bevacizumab
|
10mg/kg administered intravenously every 2 weeks
Andre navne:
150 mg/daily orally
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival
Tidsramme: From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Overall survival (OS) will be measured from the start of treatment until death from any cause.
At data cut off patients remaining alive will be censored at the last known date of contact.
|
From start of treatment, during treatment and every 3 months following the end of treatment until death. Median follow up at time of OS data was 33 months.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival at 12 Months
Tidsramme: At 12 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 12 months from start of treatment
|
Response Rate (RR)
Tidsramme: From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Response Rate (RR) will be defined as the best response seen during treatment measured by CT/MRI scan every 8 weeks during treatment using McDonald Criteria. CR=Complete disappearance of all measurable and evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients off steroids. PR=Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions. Stable/decreased dose of steroids. Stable/No Response=Does not qualify for CR, PR, or progression. The designation of Stable/No Response requires a minimum of 8 weeks duration. Stable/decreased dose of steroids. Progressive disease = 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease), worsening of evaluable disease, new lesions/site, failure to return for evaluation due to death or deteriorating condition. |
From the start of treatment, every 2 cycles (1 cycle = 28 days) during treatment until progressive disease
|
Safety of the Combination of Erlotinib and Bevacizumab in This Patient Population
Tidsramme: From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Toxicity data for combination treatment of erlotinib and bevacizumab will be collected on day 1 of every cycle (1 cycle = 28 days) during treatment according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0). In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
From the start of treatment, at the beginning of every cycle (1 cycle = 28 days) during treatment until 30 days after completion of treatment for up to 49 cycles.
|
Progression Free Survival at 18 Months
Tidsramme: At 18 months from start of treatment
|
Progression free survival (PFS) will be assessed by CT or MRI scan using McDonald criteria.
Progressive disease (PD) is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).
Stable or increased dose of steroids.
PFS will be measured from the start of treatment until first documentation of PD or death.
|
At 18 months from start of treatment
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in Tumor Blood Flow Based on MR Perfusion
Tidsramme: Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Data from consenting patients will be used to assess of changes in tumor blood flow based on MR perfusion using MRI scans.
Two scans will be completed prior to treatment on study; the first after surgery buta before radiation, the second within 14 days before starting combination treatment or erlotinib and bevacizumab.
Then scans will be completed every 2 cycles during treatment, where one cycle equals 28 days.
|
Prior to study treatment (after surgery, but before radiation), just before study treatment (within 14 days prior to first treatment) and then every 2 cycles during study treatment, where 1 cycle equals 28 days for a maximum of 49 cycles.
|
Gene Methylation Studies (Optional)
Tidsramme: At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Tissue and plasma collected from consenting patients in the study will be used to correlate tumor tissue with imaging and outcomes.
Tissue will be collected before treatment on study begins and plasma will be collected the first day of treatment (before treatment) and every odd cycle after that, whilst on study treatment.
Tissue and plasma analysis will be correlated with patients imaging results and response to to treatment
|
At baseline and then plasma only will be collected every odd cycle (1 cycle = 28 days) during treatment for a maximum of 49 cycles.
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Astrocytom
- Gliom
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Glioblastom
- Neoplasmer i nervesystemet
- Neoplasmer i centralnervesystemet
- Gliosarkom
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Proteinkinasehæmmere
- Erlotinib hydrochlorid
- Bevacizumab
Andre undersøgelses-id-numre
- NU 07C3 (Anden identifikator: Northwestern University)
- BTTC08-01 (Anden identifikator: U.T. M.D. Anderson Cancer Center)
- STU00002792 (Anden identifikator: Northwestern University IRB)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Tumorer i hjernen og centralnervesystemet
-
City of Hope Medical CenterAktiv, ikke rekrutterendeUspecificeret fast tumor i barndommen, protokolspecifik | Solid tumor | Ewing Sarkom | Uspecificeret fast tumor hos voksne, protokolspecifik | Tilbagevendende medulloblastom i barndommen | Tilbagevendende Childhood Ependymoma | Tilbagevendende neuroblastom | Tilbagevendende bløddelssarkom hos voksne | Tilbagevendende... og andre forholdForenede Stater
-
National Cancer Institute (NCI)AfsluttetUspecificeret fast tumor i barndommen, protokolspecifik | Tilbagevendende medulloblastom i barndommen | Tilbagevendende Childhood Ependymoma | Atypisk teratoid/rhabdoide tumor i barndommen | Tilbagevendende akut lymfatisk leukæmi i barndommen | T-celle stor granulær lymfocytleukæmi | T-celle akut... og andre forholdForenede Stater, Canada
-
National Cancer Institute (NCI)AfsluttetTilbagevendende Childhood Ependymoma | Tilbagevendende neuroblastom | Tilbagevendende osteosarkom | Tilbagevendende rhabdomyosarkom i barndommen | Tilbagevendende nyrecellekræft | Tilbagevendende tyktarmskræft | Tilbagevendende endetarmskræft | Tilbagevendende bløddelssarkom i barndommen | Tilbagevendende... og andre forholdForenede Stater
Kliniske forsøg med bevacizumab
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbagevendende æggelederkarcinom | Tilbagevendende ovariekarcinom | Tilbagevendende primært peritonealt karcinom | Klarcellet ovariecystadenocarcinom | Ovarial Endometrioid Adenocarcinom | Serøst cystadenocarcinom i æggestokkene | Endometrie clear cell adenocarcinoma | Endometrial serøst adenokarcinom | Tilbagevendende livmoderkræft og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterRekrutteringStadie IB hepatocellulært karcinom AJCC v8 | Fase II hepatocellulært karcinom AJCC v8 | Resektabelt hepatocellulært karcinom | Stadie I hepatocellulært karcinom AJCC v8 | Stadie IA hepatocellulært karcinom AJCC v8Forenede Stater
-
National Cancer Institute (NCI)NRG OncologyAfsluttetGlioblastom | Gliosarkom | Tilbagevendende glioblastom | Oligodendrogliom | Kæmpecelleglioblastom | Tilbagevendende hjerneneoplasmaForenede Stater, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RekrutteringTilbagevendende æggelederkarcinom | Tilbagevendende ovariekarcinom | Tilbagevendende primært peritonealt karcinom | Ovarial Endometrioid Adenocarcinom | Ovarial klarcellet adenokarcinom | Æggeleder adenocarcinom | Serøst adenokarcinom i æggelederen | Serøst adenokarcinom i æggestokkene | Æggelederkarcin... og andre forholdForenede Stater
-
National Cancer Institute (NCI)AfsluttetCervikal Adenocarcinom | Cervikal Adenosquamous Carcinom | Cervikal planocellulært karcinom, ikke andet specificeret | Stadie IVA Livmoderhalskræft AJCC v6 og v7 | Tilbagevendende cervikal karcinom | Stadie IV Livmoderhalskræft AJCC v6 og v7 | Stadie IVB Livmoderhalskræft AJCC v6 og v7Forenede Stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRekrutteringTilbagevendende æggelederkarcinom | Tilbagevendende ovariekarcinom | Tilbagevendende primært peritonealt karcinom | Tilbagevendende endometrie serøs adenokarcinom | Ovarial klarcellet adenokarcinom | Tilbagevendende platinresistent ovariekarcinom | Platinfølsomt ovariekarcinom | Tilbagevendende æggelederendometrioid... og andre forholdForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeFase IV kutan melanom AJCC v6 og v7 | Fase IIIC kutan melanom AJCC v7 | Uoperabelt melanomForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeOvarial Endometrioid Adenocarcinom | Primært peritonealt højgradigt serøst adenokarcinom | Æggeleder endometrioid adenokarcinom | Platin-resistent æggelederkarcinom | Platin-resistent primært peritonealt karcinom | Ovarial højgradigt serøst adenokarcinom | Platin-resistent ovariekarcinom | Æggeleder...Forenede Stater, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk lunge ikke-småcellet karcinom | Stadie IVA lungekræft AJCC v8 | Stadie IVB lungekræft AJCC v8 | Stadie III lungekræft AJCC v8 | Stadie IV lungekræft AJCC v8 | Stadie IIIA Lungekræft AJCC v8 | Stadie IIIB Lungekræft AJCC v8 | Stadie IIIC lungekræft AJCC v8 | Lokalt avanceret lunge ikke-småcellet... og andre forholdForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeOndartet fast neoplasma | Ovarial Endometrioid Adenocarcinom | Ovarialt udifferentieret karcinom | Cervikal Adenocarcinom | Cervikal Adenosquamous Carcinom | Ondartet peritoneal neoplasma | Endometrie clear cell adenocarcinoma | Endometrie Endometrioid Adenocarcinom | Endometrie blandet cellet adenokarcinom og andre forholdForenede Stater